Ophthalmic compositions containing loratadine
AssigneeAllergan, Inc.
InventorsChin-Ming Chang, Eldon Q. Farnes, Orest Olejnik, James N. Chang
Life of this patent
Estimating the term…
Abstract
The present invention is directed to an ophthalmic formulation which comprises a therapeutically effective amount of ethyl 4-(8-chloro-5,6-dihydro-11-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate, known as loratadine, a fatty acid ester, and a surfactant, which has been found to be useful in treating ocular allergies, especially allergic conjunctivitis, and related conditions.
Claims24
An aqueous ophthalmic emulsion composition comprising a therapeutically effective amount of loratadine, a fatty acid ester and a surfactant.
A method of treating ocular allergies in an affected person comprising administering to the eye of the affected person and effective amount of an aqueous ophthalmic emulsion composition comprising a therapeutically effective amount of loratadine, a fatty acid ester and a surfactant.
Dependencies are inferred from the claim text.